2026年11月11日,Anthropic首席执行官Dario Amodei在周二发布的42分钟IPO路演视频中预测:“癌症、阿尔茨海默病、心脏病、精神疾病——这些将成为过去的遗迹,我认为不到十年。” 2。这一关于AI医疗突破性进展的言论引发了医学界和公众的广泛质疑,其中包括礼来公司(Eli Lilly)CEO Dave Ricks等专家的反驳 12。Ricks公开表示Amodei的医疗声明不切实际,属于夸大宣传 1。德国前卫生部长Karl Lauterbach也在社交媒体X上回应称:“在短短10年内治愈这些疾病是不可能的”,并质疑Amodei是“对医学知之甚少还是故意误导公众” 2。
部分评论人士将Amodei的承诺比作Theranos创始人伊丽莎白·霍尔姆斯(Elizabeth Holmes)的过度许诺 1。圣路易斯大学拥有MD学位的AI医学研究员Melinda B. Chu指出,Anthropic自身并未展示其对实现这些目标有实质性贡献 2。生物科技高管Rami Elghandour评论称,在IPO推介中发表此类言论显得“绝望”且疯狂 2。文章作者批评主流媒体未对Amodei的言论进行深入解构,暗示这种预IPO阶段的虚假陈述可能涉及证券欺诈 1。专家指出,临床试验无法按照Amodei所述的时间表加速完成 1。尽管面临质疑,Anthropic此前已收购多家生物技术初创公司,并在湾区开设实验室探索AI在基础生物学研究中的应用 2。
Anthropic CEO Dario Amodei faced sharp criticism from industry leaders and medical experts after asserting in an IPO-related video that artificial intelligence would cure major diseases such as cancer, Alzheimer’s, heart disease, and mental illness within ten years 12. In the 42-minute roadshow video released on Tuesday, Amodei predicted these conditions would become "relics of the past," stating he believed it would take less than a decade 2. The claims, aimed at highlighting AI’s potential in drug development to support the company’s high-valuation IPO, drew immediate pushback for being unrealistic 12.
Eli Lilly CEO Dave Ricks publicly refuted Amodei’s statements, labeling them impractical exaggerations 1. Commentators compared the rhetoric to the overpromising tactics of Elizabeth Holmes, founder of Theranos, and suggested that mainstream media had failed to properly scrutinize such assertions during a pre-IPO phase where they could constitute securities fraud 1. Biotech executive Rami Elghandour echoed this skepticism, describing the remarks made during an IPO pitch as "desperate" 2.
Former German Health Minister Karl Lauterbach also dismissed the timeline as impossible, questioning whether Amodei lacked medical knowledge or was intentionally misleading the public 2. Medical experts pointed out that clinical trials cannot be accelerated to fit Amodei’s schedule 1. Melinda B. Chu, an AI medicine researcher with an MD from Saint Louis University, noted that Anthropic has not demonstrated substantive contributions toward achieving these specific cures 2. Despite Anthropic’s recent acquisitions of biotechnology startups and its establishment of labs in the Bay Area to explore AI in basic biology, researchers argued the company’s progress does not justify the projected ten-year cure window 2.
评论
还没有评论,欢迎留下第一条。